Social Cognition Training in Individuals With Huntington's Disease
1 other identifier
interventional
20
1 country
1
Brief Summary
Individuals with Huntington's Disease have impaired social cognition, which is the domain of cognition that allows individuals to understand others' perspectives so that they can navigate interpersonal actions successfully (e.g., understanding someone may be sad based of their facial emotion or tone of voice and then responding in a sympathetic manner). Impaired social cognition is associated with impaired social functioning, poor psychological wellbeing and increased caregiver burden, which is known to be significant among those who care for individuals with Huntington's Disease. Computerized social cognition training has been shown to improve social cognition in individuals with schizophrenia, who, like individuals with Huntington's disease, have cognitive impairments. The investigators propose a pilot study of computerized social cognition training in individuals with Huntington's disease. This will be a feasibility study that aims to show that social cognition training in HD can be studied in preparation for a larger randomized controlled trial. The investigators hypothesize that social cognition training can improve social cognition, social functioning, and quality of life in individuals with Huntington's Disease and decrease caregiver burden among those who care for individuals with Huntington's Disease.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Nov 2025
Typical duration for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
February 11, 2025
CompletedFirst Posted
Study publicly available on registry
February 14, 2025
CompletedStudy Start
First participant enrolled
November 15, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 15, 2027
ExpectedStudy Completion
Last participant's last visit for all outcomes
July 15, 2028
December 10, 2025
December 1, 2025
2.1 years
February 11, 2025
December 3, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (4)
Proportion of participants willing to consider study out of those who have been approached
32 months
Number of participants who adhered and completed the study
32 months
Ease of program on a scale of 1 to 5 with 5 being "very easy."
32 months
Participant satisfaction with the program
This will be a qualitative measure. The study staff will elicit from the participants what they liked about the program, what they did not like about the program, and what they would change about the program if they could.
32 months
Secondary Outcomes (6)
Change in accuracy on a facial emotion recognition task
6-12 weeks
Change in accuracy on an empathic accuracy task
6-12 weeks
Change in score on the Quality of Life in Neurological Disorders Ability to Participate in Social Roles and Activities (scores range from 45 to 225; higher score indicates better outcome)
6-12 weeks
Change in score on the Quality of Life in Neurological Disorders Satisfaction with Social Roles and Activities Questionnaire (scores range from 45 to 225; higher score indicates better outcome)
6-12 weeks
Change in score on the Quality of Life in Neurological Disorders Positive Affect and Wellbeing Questionnaire (scores range from 23 to 115; higher score indicates better outcome)
6-12 weeks
- +1 more secondary outcomes
Study Arms (1)
Social Cognition Training Group
EXPERIMENTALInterventions
Neuroplasticity-based social cognition training that targets a range of social cognition skills, including visual and vocal affect perception, social cue perception, theory of mind, self-referential style, and empathy
Eligibility Criteria
You may qualify if:
- Diagnosed with Huntington's Disease based on genetic testing
- Must be between 18 and 65 years of age
- Native English speaker who is literate in English
- Stable psychotropic medication regimen for 4 weeks
- Must have a score of "somewhat easily" on all items in the CPQ-12
- MOCA \>18
- Completed 12 years of schooling
- Access to laptop or mobile device
- Willingness to come in person 6-12 weeks after first visit
- Lives with patient
- Must be between 18 and 65 years of age
- Native English speaker who is literate in English
- MOCA \>26
- Willingness to come in person within 6-12 weeks after first visit
You may not qualify if:
- Any known neurological condition (other than Huntington's Disease).
- History of learning and/or intellectual disabilities
- Currently actively involved in any other interventional trial (i.e. have begun the intervention) or within 4 weeks of completing the final assessments of an interventional trial.
- Currently regularly completing a computerized cognitive training intervention.
- Active suicidal ideation with some intent
- Inability to provide informed consent
- Active suicidal ideation with some intent
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Rush University Medical Center
Chicago, Illinois, 60612, United States
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- OTHER
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Assistant Professor in Neurological Sciences and Psychiatry and Behavioral Sciences
Study Record Dates
First Submitted
February 11, 2025
First Posted
February 14, 2025
Study Start
November 15, 2025
Primary Completion (Estimated)
December 15, 2027
Study Completion (Estimated)
July 15, 2028
Last Updated
December 10, 2025
Record last verified: 2025-12